You are here
P&T October 2016
More than a decade of war in the Middle East has pushed post-traumatic stress disorder (PTSD) to the forefront of public health concerns. The author defines the disorder and discusses risk factors, treatments, and the barriers to effective care.
Rising acquisition costs for sodium nitroprusside, indicated for the treatment of perioperative hypertension in cardiac surgery, prompt a medical center to implement a cost-effective alternative that will result in savings of about $300,000 in 2016.
The authors present their findings after conducting a literature review of peer-reviewed articles evaluating the use of dexmedetomidine for the treatment of delirium to support the off-label use of the drug in the intensive care unit.
More than 33,000 cardiologists and allied medical professionals gathered in Rome to share the latest cardiac research. We review key sessions from a wide range of therapeutic areas, including anticoagulation, obesity, and hypercholesterolemia.
Patients with type-2 diabetes can control their blood glucose levels through diet and exercise, by losing excess weight, and by taking medications, such as first-line metformin. We examine several promising drugs in the type-2 diabetes pipeline.
Risk-reduction strategies for high-alert medication lists
Generic companies press for REMS relief with Senate bill
Approvals, new indications, regulatory activities, and more
Obeticholic acid (Ocaliva) for primary biliary cholangitis; sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic hepatitis C virus infection; and daclizumab (Zinbryta) for relapsing multiple sclerosis
Mepolizumab (Nucala) for severe eosinophilic asthma